Drug Discovery & Biotech Precision
Generalist Data Handling is a Regulatory Liability
In Drug Discovery, data is not just rows in a database—it is scientific evidence. When generalist IT vendors manage clinical data, they fail to grasp the biostatistical nuance required for high-stakes submissions. This creates a Translation Gap that leads to statistical anomalies, fragile data integrity, and costly regulatory delays.
Designial eliminates this liability. We build engineering pods where biostatisticians and pharma veterans govern the technical execution, ensuring every data point is audit-ready for the US FDA and EMA.
Agentic Solutions for Biotech Precision
Autonomous engineering pods governed by veteran biostatisticians to master your clinical data lifecycle.
The Biostats Pod
Domain-governed Phase I-IV trials and CDISC-standard statistical validation.
The Integrity Vault
Compliant data residency and regulatory-grade architecture.
The Submission Pod
Agentic CSR drafting and LLM-powered scientific reasoning for regulatory success.
Build Your Biotech Engine
Deploy your specialized Agentic AI workforce through our biostatistics-governed infrastructure to de-risk clinical trials.
The Process- Practitioner-Led Biostatistical Governance
At Designial, your technical team reports directly to our Advisory Council of biostatistics deans and clinical leaders.
Phase I: Protocol Alignment
We align your technical pod with US FDA and DCGI data standards before the first line of code is written.
Phase II: Real-Time Peer Review
Every biostatistical output undergoes forensic review by senior practitioners to ensure scientific validity.
Phase III: The Clinical Signature
Final validation for high-stakes regulatory readiness, ensuring your data is ready for institutional audit.
Consult with our Governance Council
Accelerate Your Path to Market
For Biotech scale-ups and Pharma leaders, a Designial Innovation Pod is a velocity multiplier. By establishing a domain-native hub, you reduce R&D burn by 40-60% while maintaining 100% IP ownership. We don’t just provide talent; we build your proprietary AI-native infrastructure for permanent clinical-grade scaling.
Scientific Data Governance FAQs
Compliance | How do we manage high-stakes clinical data transfers across borders?
We build private, GPU-optimized server perimeters where clinical data resides locally within its native jurisdiction. This architecture employs advanced tokenization and federated model-weight training, allowing your teams to train AI models locally and transfer only the trained model weights back to your US or EU systems, ensuring zero PII/PHI crosses borders.
Integration | Can our biostats pods integrate with legacy systems?
Yes. We design our biostatistical engineering pods with highly configurable data connectors designed to interface with traditional pharmaceutical environments (such as SAS, R, or legacy EDC platforms) without data loss or pipeline fragmentation. Our teams construct secure data mapping layers that automate SDTM/ADaM formatting and streamline trial analytics, preserving your historical data investments while preparing your infrastructure for modern, AI-native scaling.
Ownership | How does our BOT model guarantee IP sovereignty?
Under our Build-Operate-Transfer (BOT) framework, your clinical data and drug-target models never touch shared servers. We construct a 100% private, sovereign engineering hub dedicated solely to your pharma enterprise. All custom codebases, data pipelines, and trained model weights remain your exclusive intellectual property. At the end of the incubation lifecycle, we execute a seamless legal handover of the entire Indian entity and its specialized clinical talent directly to your parent company, transferring a high-value, fully compliant R&D asset to your corporate balance sheet.
Velocity | How do biostatistics pods compare to CROs?
Traditional CROs operate on a slow, manual project-by-project model. Designial’s biostatistics pods utilize Agentic AI engineered to directly process SDTM/ADaM datasets. Guided by the clinical reasoning of senior biostatisticians and 40-year FDA regulatory veterans, our autonomous agents systematically format data to CDISC standards and draft complete regulatory-grade CSRs. This practitioner-led approach reduces the administrative burden on clinical operations teams, de-risks submission data, and shortens clinical trial runways by up to 50%.
Secure Your Path to Market
Start your 90-day Clinical Catalyst pilot to de-risk your data integrity and prove 40% efficiency gains in your R&D cycle